Rush Medical College, Chicago, IL, USA.
Department of Dermatology, Northwestern University, 363 W Erie Street, Suite 350, Chicago, IL, 60654, USA.
Curr Allergy Asthma Rep. 2022 Dec;22(12):183-193. doi: 10.1007/s11882-022-01047-w. Epub 2022 Nov 8.
Biologics and small molecule inhibitors (SMIs) are a rapidly growing class of highly efficacious therapies in the treatment of chronic immunologic and allergic conditions. With precision targeting of inflammatory signaling molecules, these new agents selectively modulate the immune system to treat a variety of conditions. Dermatologic diseases, including atopic dermatitis and psoriasis, are of particular interest due to the growing number of new biologics and SMIs in recent years. This review serves to summarize and evaluate the recent literature regarding biologics and SMIs.
Currently approved biologics for AD achieve clear or almost clear skin in less than 40% of patients treated. Several biologics that are still under investigation for AD have shown better efficacy in phase III trials with similar safety profiles. Recently approved SMIs for AD also demonstrate a high degree of efficacy, but safety profiles may limit their use. Psoriasis has several highly efficacious biologics on the market; however, only one SMI is currently available. Additional SMIs for psoriasis have completed phase III trials and demonstrated high efficacy. This article evaluates recent literature on biologics and small molecule inhibitors for AD and psoriasis.
生物制剂和小分子抑制剂（SMIs）是一类治疗慢性免疫和过敏疾病的高效疗法，近年来发展迅速。这些新型药物通过精确靶向炎症信号分子，选择性调节免疫系统，从而治疗多种疾病。由于近年来新型生物制剂和 SMIs 的数量不断增加，皮肤科疾病（包括特应性皮炎和银屑病）尤其受到关注。本文旨在总结和评估近期关于生物制剂和 SMIs 的文献。
目前用于 AD 的生物制剂在不到 40%的治疗患者中实现了明显或几乎完全清除皮肤。在 AD 的 III 期临床试验中，一些正在研究的生物制剂显示出更好的疗效，且具有相似的安全性。最近批准的 AD 用 SMIs 也显示出高度的疗效，但安全性可能限制其应用。银屑病有几种高效的生物制剂上市，但目前仅有一种 SMIs。其他用于银屑病的 SMIs 已完成 III 期临床试验，显示出高疗效。本文评估了近期关于 AD 和银屑病的生物制剂和小分子抑制剂的文献。
